Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | HPGDS | O60760 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799615 | 1.00 | SMN1; SMN2 (0.61) | SMN1; SMN2LMNAHTTRAB9ANPC1 | |
| SCHEMBL5052478 | 0.89 | KDM4E (0.56) | SMN1; SMN2LMNAHTTRAB9ANPC1 | |
| SCHEMBL30016497 | 0.86 | HTT (0.60) | SMN1; SMN2LMNAHTTMEN1KMT2A | |
| SCHEMBL628989 | 0.86 | HTT (0.60) | SMN1; SMN2LMNAHTTMEN1KMT2A | |
| SCHEMBL2978070 | 0.86 | SMN1; SMN2 (0.65) | SMN1; SMN2LMNAHTTRAB9ANPC1 | |
| SCHEMBL7396688 | 0.85 | LMNA (0.51) | SMN1; SMN2LMNAHTTRAB9ANPC1 | |
| SCHEMBL10756137 | 0.85 | HPGDS (0.48) | SMN1; SMN2LMNAHTTRAB9ANPC1 | |
| SCHEMBL5051445 | 0.84 | GSK3B (0.58) | SMN1; SMN2LMNAHTTRAB9ANPC1 | |
| SCHEMBL5914630 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNAHTTRAB9ANPC1 | |
| SCHEMBL4653380 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNAHTTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958844-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-04-16 | — | — | US | disclosed |
| EP-3212636-B1 | NEW PYRIDINYLOXY- AND PHENYLOXY-PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-11-29 | — | — | EP | disclosed |
| EP-3827004-B1 | 4-(1,3,4-OXADIAZOLE-2-YL)PYRIDINE-2(1H)-ONE DERIVATIVES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS FOR THE TREATMENT OF E.G. INFECTIONS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2023-10-11 | — | — | EP | disclosed |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION | 2021-07-27 | — | — | US | disclosed |
| US-20210188831-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2021-06-24 | — | — | US | disclosed |
| EP-3827004-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2021-06-02 | — | — | EP | disclosed |
| CN-112839942-A | 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2021-05-25 | — | — | CN | disclosed |
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | OHIO UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2020-03-17 | — | — | US | disclosed |
| EP-0052930-A1 | Novel group VA salts and process for preparing same | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-06-02 | — | — | EP | disclosed |
| EP-0052931-A1 | Novel group VA ylides and process for preparing same | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-06-02 | — | — | EP | disclosed |
| EP-0046331-A2 | Nickel ylides | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-02-24 | — | — | EP | disclosed |
| EP-0046329-A1 | Process for the oligomerization of ethylene | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-02-24 | — | — | EP | disclosed |
| EP-0046328-A1 | Process for the oligomerization of ethylene in methanol | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-02-24 | — | — | EP | disclosed |
| EP-0046332-A2 | Process for the preparation of nickel ylides containing ylide ligands with a sulfonated group V component | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-02-24 | — | — | EP | disclosed |
| US-4310716-A | NICKEL YLIDE CATALYST | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
| US-4301318-A | OBTAINED BY REACTING ETHYLENE USING A NICKEL YLIDE CATALYST; SOLVENT EXTRACTION OF CATALYST USING AMMONIUM HYDROXIDE | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1981-11-17 | — | — | US | disclosed |
| US-4293727-A | CATALYSIS WITH NICKEL YLIDE | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
| US-4293502-A | CATALYST FOR OLIGOMERIZATION OF ETHYLENE | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1981-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | SMN1; SMN2 3077/4885LMNA 3874/4885HTT 3669/4885 |
| US-11958844-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | HDAC6, HDAC1, HDAC3 | SMN1; SMN2 1465/4885LMNA 4019/4885HTT 265/4885 |
| US-20210188831-A1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | SMN1; SMN2 1465/4885LMNA 4019/4885HTT 265/4885 |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | SMN1; SMN2 3067/4885LMNA 1837/4885HTT 1314/4885 |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | SMN1; SMN2 3067/4885LMNA 1837/4885HTT 1314/4885 |
| US-10633377-B2 | Imidazole and thiazole compositions for modifying biological signaling | TYRO3, FGFR1, STAT6 | SMN1; SMN2 4866/4885LMNA 3392/4885HTT 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.